Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 17/20 | 1.00 |
| ▸ | CYP26A1 | O43174 | 4/20 | 0.72 |
| ▸ | CYP26B1 | Q9NR63 | 3/20 | 0.72 |
| ▸ | RXRB | P28702 | 11/20 | 0.67 |
| ▸ | RXRG | P48443 | 6/20 | 0.66 |
| ▸ | RARB | P10826 | 5/20 | 0.66 |
| ▸ | RARG | P13631 | 5/20 | 0.66 |
| ▸ | RARA | P10276 | 3/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30012842 | 1.00 | RXRA (1.00) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7760195 | 0.87 | RXRA (0.77) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL2808583 | 0.84 | RXRA (1.00) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL8707418 | 0.84 | RXRA (0.72) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL1073645 | 0.83 | RXRA (0.70) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL726129 | 0.82 | RXRA (1.00) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL7760432 | 0.82 | RXRA (0.69) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL846110 | 0.82 | RARB (0.81) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL29827631 | 0.82 | RARB (0.81) | RXRACYP26A1CYP26B1RXRBRXRG | |
| SCHEMBL20398875 | 0.82 | RXRA (0.69) | RXRACYP26A1CYP26B1RXRBRXRG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107072991-A | Mankind's administration of inhibitors of phosphatases | 莱克斯特生物技术公司 | 2017-08-18 | — | — | CN | disclosed |
| US-20160074390-A1 | HUMAN DOSING OF PHOSPHATASE INHIBITOR | LIXTE BIOTECHNOLOGY, INC. (US) | 2016-03-17 | — | — | US | disclosed |
| EP-2185173-A1 | USE OF PHOSPHATASES TO TREAT NEUROBLASTOMAS AND MEDULLOGASTOMAS | Lixte Biotechnology, Inc. (US) | 2010-05-19 | — | — | EP | disclosed |
| WO-2009020565-A1 | USE OF PHOSPHATES TO TREAT NEUROBLASTOMAS AND MEDULLOGASTOMAS | LIXTE BIOTECHNOLOGY, INC. (US) | 2009-02-12 | — | — | WO | disclosed |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | LIXTE BIOTECHNOLOGY, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090018142-A9 | Use of phosphatases to treat tumors overexpressing N-CoR | LIXTE BIOTECHNOLOGY, INC. | 2009-01-15 | — | — | US | disclosed |
| EP-1986619-A2 | USE OF PHOSPHATASES TO TREAT TUMORS OVEREXPRESSING N-COR | Lixte Biotechnology Holdings, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080214569-A1 | Use of phosphatases to treat tumors overexpressing N-CoR | ZHUANG ZHENGPING | 2008-09-04 | — | — | US | disclosed |
| WO-2007092414-A2 | USE OF PHOSPHATASES TO TREAT TUMORS OVEREXPRESSING N-COR | LIXTE BIOTECHNOLOGY HOLDINGS, INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | JIANG GUANG LIANG | 2007-08-09 | — | — | US | disclosed |
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | JIANG GUANG LIANG | 2007-08-09 | — | — | US | disclosed |
| US-5837725-A | Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors | SRI INTERNATIONAL (US) | 1998-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160074390-A1 | HUMAN DOSING OF PHOSPHATASE INHIBITOR | PPM1A, PPP2R2A, PPM1B | RXRA 4651/4885CYP26A1 2130/4885CYP26B1 2893/4885 |
| US-20080214569-A1 | Use of phosphatases to treat tumors overexpressing N-CoR | PTPRC, PTPRCAP, PPP3CA | RXRA 244/4885CYP26A1 3802/4885CYP26B1 3707/4885 |
| US-20070185055-A1 | Method for treating cachexia with retinoid ligands | RXRA, RXRG, RXRB | RXRA 1/4885CYP26A1 752/4885CYP26B1 1109/4885 |
| US-20090018142-A9 | Use of phosphatases to treat tumors overexpressing N-CoR | PTPRC, PTPRCAP, PPP3CA | RXRA 244/4885CYP26A1 3802/4885CYP26B1 3707/4885 |
| US-20090035292-A1 | Use of phosphatases to treat neuroblastomas and medulloblastomas | PPME1, PNKP, PPP6C | RXRA 1914/4885CYP26A1 4107/4885CYP26B1 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.